Bepotastine

From Self-sufficiency
Revision as of 09:55, 6 September 2010 by Onco p53 (Talk) (clean up using AWB)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Bepotastine
File:Bepotastine.png
Systematic (IUPAC) name
4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral, topical (eye drops)
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Bioavailability High (oral)
Minimal (topical)
Protein binding ~55%
Excretion Renal (75–90%)
Identifiers
CAS Number 125602-71-3
ATC code none
PubChem CID 2350
DrugBank DB04890
ChemSpider 2260
Chemical data
Formula C21H25ClN2O3
Molar mass 388.88 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Bepotastine (Talion) is an antihistamine. It was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name TALION. TALION was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture and market bepotastine for ophthalmic use. Senju, in turn, has granted the US rights for the ophthalmic preparation to ISTA Pharmaceuticals, Inc., a specialty pharmaceutical company located in Irvine, CA.


ja:ベポタスチン